2023-01-25 07:59:00

Oxurion Announces Second Amendment to Negma Funding Program

Logo GlobeNewswire
GlobeNewswire

Oxurion Announces Second Amendment to Negma Funding Program

Leuven, BELGIUM, Boston, MA, US January 25, 2023 8:30 am Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has further amended its mandatory convertible bonds issuance and subscription agreement with the Negma Group (funding program).

Since the start of the funding program in September 2021, Negma has subscribed to EUR 11 million in convertible bonds. Pursuant to the amendment, Negma agrees to subscribe to up to EUR 4 million (1,600 bonds) in three tranches to be called at Oxurions discretion. The initial funding program totaled EUR 30 million in two parts, and pursuant to the amendment, Oxurion and Negma have mutually agreed to wind-down the funding program after the completion of the first part, which reduces the total funding under the funding program to EUR 15 million. Negma has waived the liquidity requirement and agreed to a reduced cool down period of 15 trading days, allowing Oxurion to access the full EUR 4 million over less than two months starting in February 2023 (provided the other terms and conditions of the agreement and the bonds are met).

While Oxurion continues to carefully manage its cash requirements, the Negma funding alone is not sufficient to finish Oxurions ongoing KALAHARI Phase 2, Part B clinical trial. Oxurion therefore continues to seek additional funding through debt, equity, or non-dilutive funding to support the KALAHARI trial. The KALAHARI trial is evaluating THR-149, Oxurions novel therapeutic for second line therapy, against market leader aflibercept, for the treatment of diabetic macular edema (DME) for the 40-50% of DME patients that respond suboptimally to standard of care anti-VEGF therapy. The KALAHARI trial has recruited more than 50% of the patients and topline data is currently expected before the end of 2023.

The urgency for novel therapeutics like THR-149 that could treat DME, the leading cause of blindness in working age adults, remains critical, said Tom Graney, CEO of Oxurion. Recent interim analysis of Part B of our two-part Phase 2 clinical trial of THR-149 indicated that our study should continue. We are on track to have topline results later this year as we advance our approach to developing the next generation standard of care for retinal disorders.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered forward-looking. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Companys Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Tom Graney
Chief Executive Officer Tel: +32 16 75 13 10
tom.graney@oxurion.com

US
Conway Communications
Mary T. Conway
mtconway@conwaycommsir.com

Michael Dillen
Chief Business Officer Tel: +32 479 783583
michael.dillen@oxurion.com

ICR Westwicke Christopher Brinzey Tel: +1 617 835 9304
Chris.Brinzey@westwicke.com



Attachment


Continue read on globenewswire.com

Logo GlobeNewswire
TechnologyPress Release2023-01-25 01:27:00
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Nextech AR Solutions Corp. (...

Logo EIN Presswire
Butchertown Clinical Trials facility in Louisville, Kentucky Butchertown Clinical Trials and The Eye Care Institute Announce Our 17th FDA Approval or...

Logo GlobeNewswire
SciencePress Release2023-01-24 21:01:00
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers...

Logo PR Newswire
HealthPress Release2023-01-24 18:30:00
NEW YORK, Jan. 24, 2023 /PRNewswire/ -- The ophthalmology therapeutics market by product, type, and geography - forecast and analysis 2023-2027 report has...

Logo PR Newswire
HealthPress Release2023-01-24 17:14:00
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 17:14:00
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...

Logo PR Newswire
TechnologyPress Release2023-01-24 15:00:00
These funds will be used to grow MedCrypt's engineering team in response to an increased demand for encryption and PKI solutions optimized for medical...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 10:00:00
ATUM, a global specialist and industry leader in bioengineering solutions, today announced the signing of a full licensing agreement for the Leap-In...

Logo GlobeNewswire
SciencePress Release2023-01-24 09:00:00
AVT02 as Simlandi is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure REYKJAVIK, Iceland and DUBAI, United Arab...

Logo GlobeNewswire
TechnologyPress Release2023-01-24 14:18:00
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Nextech AR Solutions Corp. (...

Logo GlobeNewswire
SciencePress Release2023-01-24 11:00:00
VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0), an autologous stem cell therapy company,...

Logo PR Newswire
HealthPress Release2023-01-24 10:56:00
Two successful exits – Syndesi and BioPhero Four portfolio companies reported clinical data from first in class targets (Galecto, NMD Pharma, Heparegenix and...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 12:36:00
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix, Inc., a privately...

Logo PR Newswire
HealthPress Release2023-01-24 18:00:00
CHICAGO, Jan. 24, 2023 /PRNewswire/ -- According to Arizton's latest research report, the therapeutic contact lenses market is to grow at a CAGR of 5% during...

Logo GlobeNewswire
SciencePress Release2023-01-23 13:30:00
Glen Rock, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (RespireRx or the Company), a leader in the discovery...

Logo PR Newswire
HealthPress Release2023-01-25 00:18:00
SEATTLE, Jan. 24, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of...

Logo PR Newswire
TechnologyPress Release2023-01-24 15:00:00
tenacio's OptiCor™ Clinical Decision Support Tool is an easy-to-use tool for clinicians to optimize treatment for patients with atrial fibrillation OptiCor™...

Logo PR Newswire
HealthPress Release2023-01-24 13:00:00
FDA's Decision Forthcoming for Innovative Test with Agency's Breakthrough Device Designation ST. LOUIS, Jan. 24, 2023 /PRNewswire/ -- Geneoscopy Inc., a life...

Logo PR Newswire
HealthPress Release2023-01-24 19:08:00
Driven by the Dobbs decision, investors seeking action on benefits, data privacy, political spending, and more SAN FRANCISCO, Jan. 24, 2023 /PRNewswire/ --...

Logo PR Newswire
HELSINKI, Jan. 25, 2023 /PRNewswire/ -- Caverion Corporation Tender Offer 24 January 2023 at 11.10 p.m. EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN...